RxDoctor Payments Data

M Zuhdi Jasser, MD

Internal Medicine · Phoenix, AZNPI 1972784866

Payments from drug & device makers

$8,337in general payments, 2019–2025

Across 471 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$676
  • Novo Nordisk$609
  • Amgen$512
  • Lilly USA, LLC$512
  • Takeda Pharmaceuticals U.S.A., Inc.$455
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$8,19198%
  • Education$1462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,337 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$598,051
Medicare patients
599
Services billed
7,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$126,771
MounjaroTirzepatide67$80,138
OzempicSemaglutide74$78,300
TrulicityDulaglutide41$56,687
ZenpepLipase/Protease/Amylase21$53,979
JanuviaSitagliptin Phosphate42$51,499
XareltoRivaroxaban27$38,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$35,717
JardianceEmpagliflozin22$34,644
MyrbetriqMirabegron45$31,279
TrintellixVortioxetine Hydrobromide19$27,665
CreonLipase/Protease/Amylase11$27,470
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$21,620
EntrestoSacubitril/Valsartan22$20,504
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$19,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$512$136,825108 claims
PfizerEliquis, Premarin$375$132,917118 claims
Novo NordiskOzempic, Wegovy$609$97,67788 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$157$57,25154 claims
MerckJanuvia$181$51,49942 claims
AbbVieCreon, Linzess, Synthroid$1,034$50,93790 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$123$49,58671 claims
Johnson & JohnsonXarelto$49$38,43727 claims
Astellas Pharma US IncMyrbetriq$328$31,27945 claims
AstraZenecaBrilinta, Farxiga$196$30,16633 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$455$27,66519 claims
NovartisEntresto$676$20,50422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →